Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Taga, Takashi  [Clear All Filters]
2023
Aoki T, Shiba N, Tsujimoto S, Yamato G, Hara Y, Kato S, Yoshida K, Ogawa S, Hayashi Y, Iwamoto S, et al. High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core-binding factor. Pediatr Blood Cancer. 2023:e30803.
Imai C, Sato A, Hiwatari M, Shimomura Y, Hori T, Suenobu S, Imamura T, Hara J, Hasegawa D, Takahashi H, et al. Outcomes following induction failure in Japanese children with acute lymphoblastic leukemia. Int J Hematol. 2023.
2022
Ozono S, Sakashita K, Yoshida N, Kakuda H, Watanabe K, Maeda M, Ishida Y, Manabe A, Taga T, Muramatsu H. A nationwide survey of late effects in survivors of juvenile myelomonocytic leukemia in Japan. Pediatr Blood Cancer. 2022:e30126.
Tomizawa D, Tsujimoto S-I, Tanaka S, Matsubayashi J, Aoki T, Iwamoto S, Hasegawa D, Nagai K, Nakashima K, Kawaguchi K, et al. A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemothe. Jpn J Clin Oncol. 2022.
2020
Hasegawa D, Tawa A, Tomizawa D, Watanabe T, Saito AMoriya, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, et al. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatr Blood Cancer. 2020:e28692.
2013
Muramatsu H, Sakaguchi H, Taga T, Tabuchi K, Adachi S, Inoue M, Kitoh T, Suminoe A, Yabe H, Azuma E, et al. Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. Pediatr Blood Cancer. 2013.